Educational information, reviewed by Ryan Arvizo, FNP-C. Current as of November 2026.
When a pharmacy compounds a medication for you, it usually starts from a bulk powder of the active ingredient, known as the API (active pharmaceutical ingredient). The pharmacy weighs it, dissolves it, fills the vial and labels it. But the pharmacy almost never made that powder. A manufacturer did, often overseas, and the only document connecting the two is a certificate of analysis. In the fall of 2026, FDA showed why that document deserves a second look.
Three warning letters about one question: who made it?
In late October and early November 2026, FDA sent warning letters to three overseas makers of active ingredients sold for compounding (FDA warning letter 734913; 736415; 736416).
- In one, FDA said it was concerned that naming that company “and not the actual manufacturer” may have been “an attempt to circumvent safeguards.” In other words, the name on the paperwork may not have been the company that made the powder.
- In the other two, the companies had declared themselves the manufacturer of ingredients shipped into the U.S. for compounding, then refused FDA’s request for records.
The products in all three letters are redacted, so nobody outside FDA can say which medications were involved. The pattern is the lesson. As one law firm summarized it, “the name on a COA may not be the true source” (ArentFox Schiff).
Why “American made” got a warning letter
On October 30, 2026, FDA warned a Texas telehealth company over its marketing of compounded semaglutide and tirzepatide. One of the problems was a video calling the products “American made.” FDA said its records showed no registered U.S. manufacturer of semaglutide or tirzepatide active ingredient for compounding, so the claim was false (FDA warning letter 737905). The same letter cited the phrase “FDA-Approved Compounded Medications” and labels that suggested the telehealth company itself compounded the drugs.
The takeaway for patients: a compounded medication can be prepared in a U.S. pharmacy and still start from an ingredient made elsewhere. “Prepared in the U.S.” and “made in the U.S.” are different claims.
What a good answer looks like
You do not need to audit a pharmacy yourself. But these are fair questions for any clinic, and a legitimate one will not be offended by them:
- Which pharmacy prepares my prescription, and in which state is it licensed? You should get a name, not “our partner pharmacy.”
- Is it a 503A pharmacy (prescription by prescription) or a 503B outsourcing facility? Both are legitimate; they are regulated differently.
- Does the pharmacy know who manufactured the active ingredient, and does the certificate of analysis name that manufacturer and its address?
- What happens if there is a recall? Who contacts you, and how?
Red flags: a clinic that cannot name its pharmacy, a product labeled “for research use only,” or marketing that calls a compounded drug “FDA-approved” or “American made.”
How BioPeakRx handles it
Every BioPeakRx prescription is prepared by a state-licensed U.S. pharmacy for you alone, after a licensed provider evaluates you. If you want to know which pharmacy prepares your medication, ask your provider.
Sources
- FDA warning letter, Nanjing Hanxin Pharmaceutical Technology Co., Ltd., 734913 (November 3, 2026)
- FDA warning letter, Tianjin Healthcare Medical Technology Co., Ltd., 736415 (October 29, 2026)
- FDA warning letter, Chongqing Qiancan Technology Co., Ltd., 736416 (October 29, 2026)
- FDA warning letter, RonanRx, Inc., 737905 (October 30, 2026)
- ArentFox Schiff, Compound interest: HHS’s new peptide policy, the China supply chain and Blue Wave
- FDA, Drug Establishments Current Registration Site
This information is educational and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved. Treatments require evaluation by a licensed provider.
